






































































































































































































































Letters to the Editor 565
dyslipidaemia often co-exists with insulin
resistance and we did not include it in our
multivariable model in order to avoid over-
adjustment.1 Similarly, as we had already
included history of myocardial infarction in
our model, addition of coronary revasculari-
sation could have created the same problem.
Nevertheless, in order to directly address
the concerns of Skelin and colleagues, we have
added both variables to our model. As can be
seen from the Table 1, this further adjustment
made little difference to our findings.
Li Shen, Pardeep Jhund, and
John McMurray∗
British Heart Foundation Cardiovascular Research
Centre, University of Glasgow, Glasgow, UK
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Letter on ‘Pharmacy-based
interdisciplinary intervention
for patients with chronic
heart failure: results of the
PHARM-CHF randomized
controlled trial’
Laufs et al.1 previously reported the design
of the PHARM-CHF (PHARMacy-based
interdisciplinary program for patients with
Chronic Heart Failure) study, the aim of which
was to investigate whether regular visits to a
community pharmacist improve adherence to
heart failure (HF) medications. Findings on the
primary endpoint showed that, in comparison
with usual care, meetings with a pharmacist
resulted in a significant 5.7% absolute increase
in the intake of the three recommended HF
medications for 365 days. Furthermore, sub-
sequent research found a more pronounced
improvement in quality of life in the interven-
tion group, but no impact on all-cause deaths
or unplanned hospitalizations compared with
the usual care group after 2 years.2
In our institution, we conducted a pre-
liminary study between January 2016 and
February 2017 with the aim of evaluating the
impact of pharmaceutical collaboration on
patients’ prescriptions according to the Euro-
pean Society of Cardiology 2016 guidelines.3
The study included 327 patients with HF with
reduced ejection fraction who were admitted
with decompensation, and showed that only
43.1% of patients were in receipt of optimal
treatment on admission, a proportion that
improved to 61.2% at discharge (P < 0.001).
Furthermore, pharmacists were involved in
the addition of recommended treatments for
between 20% and 30% of the cases. Pharma-
cists performed 62 interventions relating to
HF treatments, which included the addition
of recommended treatments (61%), dose
adjustments (22%) and treatment arrests
(8%). The results encouraged us to propose
a randomized controlled trial to evaluate the
impact of the pharmacist’s role in addition
to usual medical care (NCT03902028). Our
trial will include all adult patients hospitalized
for HF decompensation. Patients will be
randomized into a regular treatment arm or
a medical–pharmaceutical management arm.
Our primary goal is to assess the impact
of coordinated management on rates of
rehospitalization for HF decompensation
at 3 months after discharge. The interven-
tion arm will include a more collaborative
intervention with the physician and a review
of medication conducted by a pharmacist
on patient admission, as well as a proposal
for therapeutic optimization according to
European guidelines,3 to be derived using a
validated checklist. These activities will be
completed by a medication reconciliation at
discharge and patient education in order to
improve patient self-management, together
with a network of communication with
community professionals. One month after
discharge, a multidisciplinary consultation will
evaluate the efficacy, safety and impact of the
treatment plan on quality of life.
Our goal is ultimately to create an open
network between the hospital and com-
munity professionals and thereby a more
collaborative system of HF management
which might reduce rates of readmission and
HF-related mortality.
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Letter on ‘Pharmacy-based
interdisciplinary intervention
for patients with chronic
heart failure: results of the
PHARM-CHF randomized
controlled trial’: reply
We thank Dr. Kalmanovich and colleagues
for their comments on our randomized
controlled trial on improving medication
adherence and quality of life of heart failure
(HF) patients by a pharmacist-led interdis-
ciplinary approach.1 This study showed that
pharmacy care safely improved adherence
to HF medications and quality of life. These
data extend recent consensus statements of
both the Canadian Cardiovascular Society







































































































































































































































566 Letters to the Editor
guidelines for the management of HF2 and the
German clinical practice guideline on chronic
HF3 that acknowledge the available evidence
of pharmacist care and interdisciplinary
care.4,5 Topics and tasks include prevention
of HF, particularly by improving adherence
to antihypertensives, providing medication
reviews, assuring appropriate self-medication,
and improving both medication safety and
adherence.4 We congratulate Kalmanovich
et al. to their research plan. Their study
will hopefully provide additional randomized
evidence for the effects of interdisciplinary
care in patients with HF.
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Survival rates in elderly
patients with heart failure
We read with interest the article by Jones
et al.1 which analysed the survival rates of
patients in the community with chronic heart
failure (HF). It is notable that in patients
aged ≤ 65 years, the rates of survival were
almost 10% and 30% better at 1 and 5 years,
respectively, when compared to those aged
≥ 75 years. This may be due to co-morbidities
in the older population, but another possi-
bility may be due to these patients not being
put on adequate HF medications.
Molnar et al.2 have shown that the survival
benefit of beta-blockers in chronic HF could
be extrapolated to elderly patients with
advanced chronic kidney disease (CKD). In
a retrospective cohort study involving 5862
elderly patients with advanced CKD, the
group showed reduced all-cause mortality
with beta-blocker use.
Similarly, Martínez-Milla et al.3 performed a
single-centre, observational cohort study on
390 patients aged ≥75 years with CKD who
were in receipt of angiotensin-converting
enzyme inhibitors/angiotensin receptor
blockers (ACEi/ARBs) and mineralocorticoid
receptor antagonists (MRAs). Their findings
showed that ACEi/ARB treatment was associ-
ated with fewer cardiovascular events, whilst
MRAs did not reduce the number of this nor
influence total mortality.
Anaemia, which is common in elderly HF
patients, is associated with a worse prognosis,
as shown by Savarese et al.4 The group looked
at the Swedish Heart Failure registry data
of 49 985 patients and found that anaemia is
associated with worse prognosis in both HF
with preserved ejection fraction and HF with
reduced ejection fraction. These patients
have received more aggressive treatment
with intravenous iron infusions over the last
few years. It would be useful to have data, if
available from the papers in this meta-analysis,
on this correlation and whether treatment
improved prognosis, especially in the elderly.
With newer agents such as empagliflozin
not yet in wider usage but shown to improve
mortality in HF,5 it would be interesting to see
how future data will be affected, particularly in
the elderly population who also tend to have
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Survival rates in elderly
patients with heart
failure: reply
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